최호순
2021-04-15T02:26:50Z
2021-04-15T02:26:50Z
2020-02
Journal of Liver Cancer, v. 20, no. 1, page. 67-71
2288-8128
2383-5001
https://www.e-jlc.org/journal/view.php?doi=10.17998/jlc.20.1.67
https://repository.hanyang.ac.kr/handle/20.500.11754/161412
Tyrosine kinase inhibitors are widely used as targeted treatments for various malignancies. Sorafenib is an orally active tyrosine kinase inhibitor that blocks the signaling pathways of several growth factors. Its use is approved for various malignancies such as unresectable hepatocellular carcinoma, renal cell carcinoma, and gastrointestinal stromal tumors. Several adverse effects have been reported in the literature; however, cardiotoxicity is rare. We present a case of recurrent coronary vasospasm caused by short-term administration (5 days) of sorafenib. Since it caused refractory ischemia after re-administration, we had no choice but to stop the treatment.
en
The Korean Liver Cancer Association
Sorafenib
Coronary artery vasospasm
Variant angina
Tyrosine kinase inhibitor
Vascular endothelial growth factor inhibitor
Recurrent Coronary Artery Vasospasm in a Patient with Hepatocellular Carcinoma Treated with Sorafenib: a Case Report and Literature Review
Article
1
20
10.17998/jlc.20.1.67
67-71
Journal of Liver Cancer
Lim, Dae Hyun
Yoon, Jai Hoon
Jun, Dae Won
Lee, Oh Young
Yoon, Byung Chul
Lee, Hang Rak
Kim, Kyung Soo
Choi, Ho Soon
2020041022
S
COLLEGE OF MEDICINE[S]
DEPARTMENT OF MEDICINE
hschoi96
http://orcid.org/0000-0003-3746-8742